Rise in demand of glp-1 drugs for metabolic disorders.

In recent years, owing to its broader clinical potential in the treatment of obesity and type 2 diabetes, along with their proven efficacy in reducing cardiovascular risks, GLP-1 drugs market has garnered significant traction within the medical science domain.
Concurrently, the rising demand and escalating prevalence of metabolic disorder including type 2 diabetes and obesity are fueling the need for treatments capable of effectively managing these conditions. This trend is expected to drive innovation and stimulate market growth within this sector.
The global GLP-1 market, valued at USD 49.3 billion in 2024, is estimated to reach USD 62.2 billion in 2025 and USD 157.5 billion by 2035, representing a CAGR of 9.7% during the forecast period.
To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/glp-1-market/request-quote.html

Over the years, rise in the demand of GLP-1 drugs has increased the research activity in this domain. The rich pipeline of GLP-1 drugs is also driving growth in the GLP-1 market, as the conditions like obesity is on the rise, more patients and doctors are looking for treatment options. As the market climbs higher, addressing issues of cost and availability will be essential in making sure that the advantages of GLP-1 medications are accessible to a broader group of people. With ongoing research and development, we anticipate further progress in this area, leading to a new period of managing metabolic conditions.
The current market landscape features the presence of more than 150 GLP-1 drug candidates, intended for the treatment of multiple indications, are currently either approved or being investigated by pharmaceutical companies, that are currently available in the market or under different stages of development.

To request a sample copy / brochure of this report, please visit:
https://www.rootsanalysis.com/reports/glp-1-market/request-sample.html

Majority (close to 60%) of the GLP-1 drug candidates are currently being evaluated in clinical stages of development; of these, most of the candidates target metabolic disorders, such as Type 2 diabetes and obesity. Notably, 11% GLP-1 drugs candidates are approved by various regulatory body across the globe.
Further, most (56%) of the GLP-1 drugs are currently being evaluated as a single agonist followed by dual-agonist (32%) and tri-agonist (12%) for the treatment of various metabolic and other disorders; examples of tri-agonist include (in alphabetical order, phase II / phase III studies) DR10624 (Doer Biologics), Efocipegtrutide, HM15211 (Hanmi Pharmaceutical), HM15275 (Hanmi Pharmaceutical), MWN101 (Shanghai Minwei Biotechnology), Retatrutide, LY3437943 (Eli Lilly) and UBT251 (United Bio-Technology)
The GLP-1 market is highly fragmented, featuring the presence of well-established as well as emerging players. The GLP-1 market is currently dominated by the presence of mid-sized companies (27%). This is followed by small (25%) and very large companies (21%).

To request a sample copy / brochure of this report, please visit:
https://www.rootsanalysis.com/reports/glp-1-market.html

The latest research report specializes in the in-depth analysis of the macroeconomic and microeconomic factors affecting the GLP-1 Market development. The report also concentrates on the regulatory framework that is shaping the future of the global market. New and existing pricing structures, emerging application areas, and upcoming investment opportunities have also been detailed in the report. The report further studies the projected growth factors that are expected to influence the market dynamics over the forecast timeframe.

The study is inclusive of a comprehensive analysis of the commonly used marketing and promotional strategies adopted by the key market players. Taking into account the existing market development factors, historical events, and recent market trends, the study presents a balanced opinion on the future scenario of the GLP-1 Market. It thus supports its opinion by discussing the key corporate strategies, such as mergers & acquisitions, takeovers, joint ventures, and strategic alliances, used by the market players to strengthen their global footprint.

Contact Details for Roots Analysis
Chief Executive: Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.